| Jay R Brewer, CRNA | |
|
105 E Locust St, Bloomfield, IA 52537-1458 | |
| (641) 664-3602 | |
| (641) 664-3765 |
| Full Name | Jay R Brewer |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 30 Years |
| Location | 105 E Locust St, Bloomfield, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174633002 | NPI | - | NPPES |
| 430059427 | Other | RAILROAD MEDICARE | |
| 0206177 | Medicaid | IA | |
| 16605 | Other | IA | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | D099449 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercyone Centerville Medical Center | Centerville, IA | Hospital |
| Jefferson County Health Center | Fairfield, IA | Hospital |
| Monroe County Hospital | Albia, IA | Hospital |
| Davis County Hospital | Bloomfield, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Jefferson County Hospital | 9335059575 | 41 |
News Archive
The failure of California's infectious disease monitoring system for a stretch of at least 20 days in July and August triggered potentially deadly fallout that continues to reverberate across the state.
New research has found some compounds effective in blocking the proliferation of certain bacteria, raising hopes of a new class of drugs to combat antibiotic resistant infections
Pro-Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted an Investigational New Drug (IND) application for use of Davanat in combination with 5-FU to treat a breast cancer patient at the Brown Cancer Center in Louisville, Kentucky. Davanat also is being administered in Phase II clinical trials for first-line treatment of colorectal and biliary cancer patients.
Bloomberg: "Maine wants an exemption from the federal health-care law to keep a Wall Street-controlled insurer with a history of allegedly abusive practices from leaving the state. Mila Kofman, Maine's insurance superintendent, asked the U.S. Department of Health and Human Services for a three-year waiver from the law's requirement that insurers spend 80 percent of premium revenues on medical care." The
Celldex Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2010. Celldex reported a net loss of $6.6 million, or $0.21 per share, for the first quarter of 2010 compared to a net loss of $7.7 million, or $0.49 per share, for the first quarter of 2009. At March 31, 2010, Celldex reported cash, cash equivalents and marketable securities of $75.4 million, which the Company believes will be sufficient to meet estimated working capital requirements and fund operations into 2012.
› Verified 5 days ago
| Entity Name | Jefferson County Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881294536 PECOS PAC ID: 9335059575 Enrollment ID: O20031223000606 |
News Archive
The failure of California's infectious disease monitoring system for a stretch of at least 20 days in July and August triggered potentially deadly fallout that continues to reverberate across the state.
New research has found some compounds effective in blocking the proliferation of certain bacteria, raising hopes of a new class of drugs to combat antibiotic resistant infections
Pro-Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted an Investigational New Drug (IND) application for use of Davanat in combination with 5-FU to treat a breast cancer patient at the Brown Cancer Center in Louisville, Kentucky. Davanat also is being administered in Phase II clinical trials for first-line treatment of colorectal and biliary cancer patients.
Bloomberg: "Maine wants an exemption from the federal health-care law to keep a Wall Street-controlled insurer with a history of allegedly abusive practices from leaving the state. Mila Kofman, Maine's insurance superintendent, asked the U.S. Department of Health and Human Services for a three-year waiver from the law's requirement that insurers spend 80 percent of premium revenues on medical care." The
Celldex Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2010. Celldex reported a net loss of $6.6 million, or $0.21 per share, for the first quarter of 2010 compared to a net loss of $7.7 million, or $0.49 per share, for the first quarter of 2009. At March 31, 2010, Celldex reported cash, cash equivalents and marketable securities of $75.4 million, which the Company believes will be sufficient to meet estimated working capital requirements and fund operations into 2012.
› Verified 5 days ago
| Entity Name | Wayne County Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174599468 PECOS PAC ID: 4082508734 Enrollment ID: O20040212000233 |
News Archive
The failure of California's infectious disease monitoring system for a stretch of at least 20 days in July and August triggered potentially deadly fallout that continues to reverberate across the state.
New research has found some compounds effective in blocking the proliferation of certain bacteria, raising hopes of a new class of drugs to combat antibiotic resistant infections
Pro-Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted an Investigational New Drug (IND) application for use of Davanat in combination with 5-FU to treat a breast cancer patient at the Brown Cancer Center in Louisville, Kentucky. Davanat also is being administered in Phase II clinical trials for first-line treatment of colorectal and biliary cancer patients.
Bloomberg: "Maine wants an exemption from the federal health-care law to keep a Wall Street-controlled insurer with a history of allegedly abusive practices from leaving the state. Mila Kofman, Maine's insurance superintendent, asked the U.S. Department of Health and Human Services for a three-year waiver from the law's requirement that insurers spend 80 percent of premium revenues on medical care." The
Celldex Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2010. Celldex reported a net loss of $6.6 million, or $0.21 per share, for the first quarter of 2010 compared to a net loss of $7.7 million, or $0.49 per share, for the first quarter of 2009. At March 31, 2010, Celldex reported cash, cash equivalents and marketable securities of $75.4 million, which the Company believes will be sufficient to meet estimated working capital requirements and fund operations into 2012.
› Verified 5 days ago
| Entity Name | Mercy Medical Center-centerville |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528018801 PECOS PAC ID: 9739077652 Enrollment ID: O20040310000762 |
News Archive
The failure of California's infectious disease monitoring system for a stretch of at least 20 days in July and August triggered potentially deadly fallout that continues to reverberate across the state.
New research has found some compounds effective in blocking the proliferation of certain bacteria, raising hopes of a new class of drugs to combat antibiotic resistant infections
Pro-Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted an Investigational New Drug (IND) application for use of Davanat in combination with 5-FU to treat a breast cancer patient at the Brown Cancer Center in Louisville, Kentucky. Davanat also is being administered in Phase II clinical trials for first-line treatment of colorectal and biliary cancer patients.
Bloomberg: "Maine wants an exemption from the federal health-care law to keep a Wall Street-controlled insurer with a history of allegedly abusive practices from leaving the state. Mila Kofman, Maine's insurance superintendent, asked the U.S. Department of Health and Human Services for a three-year waiver from the law's requirement that insurers spend 80 percent of premium revenues on medical care." The
Celldex Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2010. Celldex reported a net loss of $6.6 million, or $0.21 per share, for the first quarter of 2010 compared to a net loss of $7.7 million, or $0.49 per share, for the first quarter of 2009. At March 31, 2010, Celldex reported cash, cash equivalents and marketable securities of $75.4 million, which the Company believes will be sufficient to meet estimated working capital requirements and fund operations into 2012.
› Verified 5 days ago
| Entity Name | Davis County Hospital |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1942255666 PECOS PAC ID: 3971493040 Enrollment ID: O20061129000182 |
News Archive
The failure of California's infectious disease monitoring system for a stretch of at least 20 days in July and August triggered potentially deadly fallout that continues to reverberate across the state.
New research has found some compounds effective in blocking the proliferation of certain bacteria, raising hopes of a new class of drugs to combat antibiotic resistant infections
Pro-Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted an Investigational New Drug (IND) application for use of Davanat in combination with 5-FU to treat a breast cancer patient at the Brown Cancer Center in Louisville, Kentucky. Davanat also is being administered in Phase II clinical trials for first-line treatment of colorectal and biliary cancer patients.
Bloomberg: "Maine wants an exemption from the federal health-care law to keep a Wall Street-controlled insurer with a history of allegedly abusive practices from leaving the state. Mila Kofman, Maine's insurance superintendent, asked the U.S. Department of Health and Human Services for a three-year waiver from the law's requirement that insurers spend 80 percent of premium revenues on medical care." The
Celldex Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2010. Celldex reported a net loss of $6.6 million, or $0.21 per share, for the first quarter of 2010 compared to a net loss of $7.7 million, or $0.49 per share, for the first quarter of 2009. At March 31, 2010, Celldex reported cash, cash equivalents and marketable securities of $75.4 million, which the Company believes will be sufficient to meet estimated working capital requirements and fund operations into 2012.
› Verified 5 days ago
| Entity Name | Van Buren County Hospital |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1508810714 PECOS PAC ID: 7214829530 Enrollment ID: O20100908000821 |
News Archive
The failure of California's infectious disease monitoring system for a stretch of at least 20 days in July and August triggered potentially deadly fallout that continues to reverberate across the state.
New research has found some compounds effective in blocking the proliferation of certain bacteria, raising hopes of a new class of drugs to combat antibiotic resistant infections
Pro-Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted an Investigational New Drug (IND) application for use of Davanat in combination with 5-FU to treat a breast cancer patient at the Brown Cancer Center in Louisville, Kentucky. Davanat also is being administered in Phase II clinical trials for first-line treatment of colorectal and biliary cancer patients.
Bloomberg: "Maine wants an exemption from the federal health-care law to keep a Wall Street-controlled insurer with a history of allegedly abusive practices from leaving the state. Mila Kofman, Maine's insurance superintendent, asked the U.S. Department of Health and Human Services for a three-year waiver from the law's requirement that insurers spend 80 percent of premium revenues on medical care." The
Celldex Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2010. Celldex reported a net loss of $6.6 million, or $0.21 per share, for the first quarter of 2010 compared to a net loss of $7.7 million, or $0.49 per share, for the first quarter of 2009. At March 31, 2010, Celldex reported cash, cash equivalents and marketable securities of $75.4 million, which the Company believes will be sufficient to meet estimated working capital requirements and fund operations into 2012.
› Verified 5 days ago
| Entity Name | Bloomfield Anesthetists |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811091390 PECOS PAC ID: 1557529948 Enrollment ID: O20120214000539 |
News Archive
The failure of California's infectious disease monitoring system for a stretch of at least 20 days in July and August triggered potentially deadly fallout that continues to reverberate across the state.
New research has found some compounds effective in blocking the proliferation of certain bacteria, raising hopes of a new class of drugs to combat antibiotic resistant infections
Pro-Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted an Investigational New Drug (IND) application for use of Davanat in combination with 5-FU to treat a breast cancer patient at the Brown Cancer Center in Louisville, Kentucky. Davanat also is being administered in Phase II clinical trials for first-line treatment of colorectal and biliary cancer patients.
Bloomberg: "Maine wants an exemption from the federal health-care law to keep a Wall Street-controlled insurer with a history of allegedly abusive practices from leaving the state. Mila Kofman, Maine's insurance superintendent, asked the U.S. Department of Health and Human Services for a three-year waiver from the law's requirement that insurers spend 80 percent of premium revenues on medical care." The
Celldex Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2010. Celldex reported a net loss of $6.6 million, or $0.21 per share, for the first quarter of 2010 compared to a net loss of $7.7 million, or $0.49 per share, for the first quarter of 2009. At March 31, 2010, Celldex reported cash, cash equivalents and marketable securities of $75.4 million, which the Company believes will be sufficient to meet estimated working capital requirements and fund operations into 2012.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jay R Brewer, CRNA Po Box 54, Bloomfield, IA 52537-0054 Ph: (641) 664-3602 | Jay R Brewer, CRNA 105 E Locust St, Bloomfield, IA 52537-1458 Ph: (641) 664-3602 |
News Archive
The failure of California's infectious disease monitoring system for a stretch of at least 20 days in July and August triggered potentially deadly fallout that continues to reverberate across the state.
New research has found some compounds effective in blocking the proliferation of certain bacteria, raising hopes of a new class of drugs to combat antibiotic resistant infections
Pro-Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted an Investigational New Drug (IND) application for use of Davanat in combination with 5-FU to treat a breast cancer patient at the Brown Cancer Center in Louisville, Kentucky. Davanat also is being administered in Phase II clinical trials for first-line treatment of colorectal and biliary cancer patients.
Bloomberg: "Maine wants an exemption from the federal health-care law to keep a Wall Street-controlled insurer with a history of allegedly abusive practices from leaving the state. Mila Kofman, Maine's insurance superintendent, asked the U.S. Department of Health and Human Services for a three-year waiver from the law's requirement that insurers spend 80 percent of premium revenues on medical care." The
Celldex Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2010. Celldex reported a net loss of $6.6 million, or $0.21 per share, for the first quarter of 2010 compared to a net loss of $7.7 million, or $0.49 per share, for the first quarter of 2009. At March 31, 2010, Celldex reported cash, cash equivalents and marketable securities of $75.4 million, which the Company believes will be sufficient to meet estimated working capital requirements and fund operations into 2012.
› Verified 5 days ago
Melissa M Mahon, CRNA/ARNP Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 105 E Locust St, Bloomfield, IA 52537 Phone: 641-664-3602 Fax: 641-664-3765 | |
Valerie K Mckinley, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 105 E Locust St, Bloomfield, IA 52537 Phone: 641-664-3602 Fax: 641-664-3765 | |
Mrs. Sara Katherine Mullahy, CRNA, ARNP Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 105 E Locust St, Bloomfield, IA 52537 Phone: 641-664-3602 Fax: 641-664-3765 | |
Jackie K Lauer, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 505 W Jefferson St, Bloomfield, IA 52537 Phone: 641-664-3602 Fax: 641-664-3765 | |
Mr. Mark James Gallion, Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 105 E Locust St, Bloomfield, IA 52537 Phone: 641-664-3602 | |
Marty J Owen, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 505 W Jefferson St, Bloomfield, IA 52537 Phone: 641-664-3602 Fax: 641-664-3765 |